Clinical development plan leveraging 505(b)(2) regulatory pathwayInitiation of Phase 2a biomarker study on track to start before year endCurrently available treatments for IPF are limited to only two approved drugs that
Summary of Financial Results for Third Quarter 2023Net loss was $11.0 million for the nine months ended September 30, 2023.Research and development expenses were $2.2 million and $0.2 million for the nine months ended